Ocular Therapeutix Stock News

What happened in the stock market today and Penny stocks to watch this week. The post Stock Market Today: What Happened & 3 Penny Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News

Ocular (OCUL) interim seven-month data on OTX-TKI from a phase I study for treating wet age-related macular degeneration (wet AMD) shows a favorable safety profile, and stable and sustained visual acu

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera

Shares have lost a quarter of their value so far this year. Dextenza sales are reaccelerating after a tough performance due to pandemic-related challenges.

The market doesn't fully appreciate that OCUL was granted a late-breaking slot at the September 30 AAO conference to present its OTX-TKI Phase 1 data in wet AMD. I review wet AMD, the current standard

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Donald Notman - CFO Antony Mattessich - President, CEO & Director Rabia Ozden -

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Donald Notman – Chief Financial Officer Antony Mattessich – President & Chief E

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases

Ocular Therapeutix: A Follow-Up

Ocular Therapeutix Inc. (NASDAQ:OCUL) shares, rose in value on Friday, 03/11/22, with the stock price down by -3.80% to the previous day’s close as strong demand from buyers drove the stock to $5.31. Actively observing the price movement in the last trading, the stock closed the session at $5.52, falling within a range of $5.31 … Is Ocular Therapeutix Inc. (NASDAQ) Bullish Or Bearish In 2022? Read More »

Blue Sky potential due to potential blockbuster candidates with a differentiated mechanism of action.

Ocular Therapeutix Inc. (NASDAQ:OCUL)’s traded shares stood at 0.54 million during the last session, with the company’s beta value hitting 1.72. At the close of trading, the stock’s price was $4.93, to imply a decrease of -2.95% or -$0.15 in intraday trading. The OCUL share’s 52-week high remains $21.48, putting it -335.7% down since that … Ocular Therapeutix Inc. (NASDAQ: OCUL) Shares Fall By -10.69 Percent In The Past Week, But How Long Will It Last? Read More »

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera